Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW2821 and Toripalimab in perioperative urothelial cancer
NCT07314723Phase 2Recruiting
- Sponsor
- Mabwell
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bulumtatug fuvedotin in urothelial carcinoma (UC), sponsored by Mabwell. Started Aug 2025; status: recruiting.
02
Drugs
bulumtatug fuvedotin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07314723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07314723.